Bradley Gill, MD
Urology · Mayfield Heights, OHNPI 1518223106
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $90,050 of the $139,589 with a category attached, or 64.5%. Boston Scientific accounts for 74.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $56,420 and has fallen 54.5% since, to $25,698 in 2025. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $386.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$104K
- Sumitomo Pharma America, Inc.$26K
- Medtronic$4K
- Urovant Sciences Inc$3K
- Procept Biorobotics Corporation$364
- Coloplast$362
- plus $2K from 15 others
Across 22 payments — averaging $2086.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$22K
- Medtronic$9K
- Sumitomo Pharma America, Inc.$8K
- Urovant Sciences Inc$7K
What the payments were for
- Consulting fees$90,05065%
- Speaking & faculty fees$20,08514%
- Travel & lodging$15,07311%
- Food & beverage$14,13610%
- Education$2450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 253 | $103,863 |
| Sumitomo Pharma America, Inc. | 13 | $25,609 |
| Medtronic(2 entities) | 43 | $4,339 |
| Urovant Sciences Inc | 8 | $3,230 |
| Procept Biorobotics Corporation | 3 | $364 |
| Coloplast | 3 | $362 |
| Antares Pharma, Inc. | 2 | $269 |
| Axonics, Inc. | 3 | $264 |
| Neotract Inc. | 2 | $230 |
| Astellas Pharma US Inc | 7 | $167 |
| Endo Pharmaceuticals Inc. | 5 | $148 |
| Johnson & Johnson | 4 | $147 |
| AbbVie | 1 | $142 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $138 |
| Intuitive Surgical | 2 | $133 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Novo Nordisk | 2 | $35 |
| Richard Wolf Medical Instruments Corp. | 2 | $31 |
| Pfizer | 2 | $24 |
| Novartis | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$27,427
- GEMTESA$12,870
- AMS$5,042
- GreenLight XPS$3,503
- GENERAL - THERAPIES$3,109
- INTERSTIM$2,604
- rezum Generator$2,375
- AMS 800 Artificial Urinary Sphincter$1,294
- AMS 700$1,187
- ALTAVIVA$874
- Axonics$384
- TITAN$343
- AQUABEAM SYSTEM$257
- Bulkamid$257
- AMS 700 CXR RTE KIT$222
- LithoVue$170
- BOTOX$142
- NOCDURNA$138
- UroLift$135
- XYOSTED$130
How this compares
$139,589 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 85 | $73,740 |
| GemtesaVibegron | 30 | $24,392 |
| Finasteride | 405 | $5,531 |
| Tamsulosin Hcl | 256 | $3,924 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,409 |
| Trospium Chloride | 30 | $2,280 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 46 | $1,280 |
| Dutasteride | 12 | $493 |
| Ciprofloxacin Hcl | 20 | $174 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $162 |
| Cephalexin | 46 | $148 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $120 |
| Doxycycline Hyclate | 19 | $108 |
| Amoxicillin | 15 | $30 |
| Oxycodone Hcl | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $167 | $73,74085 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25,609 | $24,39230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Mayfield Heights
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.